Loading clinical trials...
Loading clinical trials...
This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Duramed Research
NCT05902078 · Low Bone Mineral Density, Postmenopausal Osteoporosis
NCT04900506 · Femoral Neck Fractures, Bone Mineral Density, and more
NCT01419730 · Bone Metabolism Biomarkers, Bone Mineral Density, and more
NCT05461573 · Contraception, Change in Bone Mineral Density
NCT06614374 · Cognitive Decline, Sleep, and more
Teva Investigational Site 007
Phoenix, Arizona
Teva Investigational Site 018
Phoenix, Arizona
Teva Investigational Site 005
Tucson, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions